Biospring Partners

Abzena is a provider of services and technologies that facilitate the selection, development, and manufacturing of biopharmaceutical products on a global scale, with operations in North America and Europe. The company specializes in antibody drug conjugates (ADCs), offering proprietary technologies such as ThioBridge and solutions for antibody humanization, protein deimmunization, and immunogenicity assessment. Abzena supports the discovery and development of antibodies through its phage display, Hybridoma sequencing, and developability assessment solutions. Additionally, it provides extensive bioassays and bioanalytics to characterize drug-conjugates and assess candidate selection. The company also engages in the contract development and manufacturing of various biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapy products. With a diverse client base that includes major biopharmaceutical companies and academic institutions, Abzena aims to enhance therapeutic innovation through its comprehensive suite of services and technologies. Established in 2014, the company is headquartered in Cambridge, United Kingdom.

Kiniciti is a platform created by Welsh, Carson, Anderson & Stowe, dedicated to partnering with companies that aim to enhance the cell and gene therapy ecosystem. The organization seeks to address the challenges that impede the development, manufacturing, and delivery of innovative therapies, which often hinder access for patients. By providing resources, expertise, and capital, Kiniciti focuses on opportunities that leverage technology to drive significant change in the life sciences sector. Its mission is to enable the efficient scaling of life science companies, ensuring that promising therapies reach the patients who need them most while maintaining economic viability.

ixlayer enables leading health systems, clinical labs, biopharma, and consumer companies to offer precision health testing, by remove all the technical, security, and regulatory complexity involved in launching a clinical health test.

Abzena is a provider of services and technologies that facilitate the selection, development, and manufacturing of biopharmaceutical products on a global scale, with operations in North America and Europe. The company specializes in antibody drug conjugates (ADCs), offering proprietary technologies such as ThioBridge and solutions for antibody humanization, protein deimmunization, and immunogenicity assessment. Abzena supports the discovery and development of antibodies through its phage display, Hybridoma sequencing, and developability assessment solutions. Additionally, it provides extensive bioassays and bioanalytics to characterize drug-conjugates and assess candidate selection. The company also engages in the contract development and manufacturing of various biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapy products. With a diverse client base that includes major biopharmaceutical companies and academic institutions, Abzena aims to enhance therapeutic innovation through its comprehensive suite of services and technologies. Established in 2014, the company is headquartered in Cambridge, United Kingdom.